04:20 AM EDT, 07/29/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said late Monday the US Food and Drug Administration has approved its Empaveli drug as the first treatment for kidney diseases C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis in patients aged 12 years and older.

The company said the approval was based on data from a phase 3 trial in which Empaveli showed a "68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits as measured by C3 staining, compared to placebo."